ALK-Abello B (ALKb)

Currency in DKK
213.80
-6.20(-2.82%)
Real-time Data·
ALKb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
212.20218.80
52 wk Range
130.70237.60
Key Statistics
Prev. Close
220
Open
218.2
Day's Range
212.2-218.8
52 wk Range
130.7-237.6
Volume
35.14K
Average Volume (3m)
169.47K
1-Year Change
41.6832%
Book Value / Share
29.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALKb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
255.00
Upside
+19.27%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

ALK-Abello B News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

ALK-Abello B Company Profile

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy’s Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Employees
2613
Market
Denmark

Compare ALKb to Peers and Sector

Metrics to compare
ALKb
Peers
Sector
Relationship
P/E Ratio
40.6x22.5x−0.5x
PEG Ratio
0.87−0.140.00
Price/Book
7.5x4.4x2.6x
Price / LTM Sales
7.7x2.9x3.2x
Upside (Analyst Target)
16.1%26.7%47.3%
Fair Value Upside
Unlock20.1%6.7%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 255.00
(+19.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.40%
Dividend Yield
0.73%
Industry Median 3.62%
Annualised payout
1.60
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 20, 2026
EPS / Forecast
1.20 / 1.60
Revenue / Forecast
1.73B / 1.71B
EPS Revisions
Last 90 days

ALKb Income Statement

People Also Watch

233.3
NOVOb
-1.58%
1,812.0
GMAB
-2.71%
473.4
COLOb
-1.95%
187.9
DEMANT
-4.47%
18.11
DAST
-1.98%

FAQ

What Is the ALK-Abello B (ALKb) Stock Price Today?

The ALK-Abello B stock price today is 213.80 DKK.

What Stock Exchange Does ALK-Abello B Trade On?

ALK-Abello B is listed and trades on the Copenhagen Stock Exchange.

What Is the Stock Symbol for ALK-Abello B?

The stock symbol for ALK-Abello B is "ALKb."

What Is the ALK-Abello B Market Cap?

As of today, ALK-Abello B market cap is 47.02B DKK.

What Is ALK-Abello B's Earnings Per Share (TTM)?

The ALK-Abello B EPS (TTM) is 5.40.

When Is the Next ALK-Abello B Earnings Date?

ALK-Abello B will release its next earnings report on May 05, 2026.

From a Technical Analysis Perspective, Is ALKb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has ALK-Abello B Stock Split?

ALK-Abello B has split 1 times.

How Many Employees Does ALK-Abello B Have?

ALK-Abello B has 2613 employees.

What is the current trading status of ALK-Abello B (ALKb)?

As of Mar 03, 2026, ALK-Abello B (ALKb) is trading at a price of 213.80 DKK, with a previous close of 220.00 DKK. The stock has fluctuated within a day range of 212.20 DKK to 218.80 DKK, while its 52-week range spans from 130.70 DKK to 237.60 DKK.

What Is ALK-Abello B (ALKb) Price Target According to Analysts?

The average 12-month price target for ALK-Abello B is 255.00 DKK, with a high estimate of 255 DKK and a low estimate of 255 DKK. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +19.27% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.